AMP RA/SLE Leadership Center

AMP RA/SLE 领导中心

• 批准号: 9913030
• 负责人: Vernon Michael Holers
• 金额: $ 84.9万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-24 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9913030
• 关键词: 3-Dimensional; Affect; Aftercare; Antirheumatic Agents; Applied Research; Archives; Area; Autoimmune Diseases; Autoimmune Process; Automobile Driving; Basic Science; Bioinformatics; Biological; Biology; Biopsy; Biotechnology; Blood; Budgets; Cells; Clinical; Clinical Research; Collaborations; Collection; Communities; Computers; Consent Forms; Cryopreservation; Data; Data Quality; Data Set; Databases; Development; Disease; Disease Pathway; Drug Industry; Drug or chemical Tissue Distribution; Ensure; Faculty; Foundations; Funding; Future; Goals; Individual; Inflammatory; Informatics; Information Dissemination; Infrastructure; Institution; Institutional Review Boards; Intake; International; Kidney; Kidney Diseases; Laboratories; Leadership; Lupus; Measures; Methodology; Methods; Mission; Modeling; National Institute of Allergy and Infectious Disease; Organ; Pathway interactions; Patients; Performance; Phase; Pilot Projects; Policies; Procedures; Process; Program Sustainability; Protocols documentation; Publications; RNA Interference; Research; Research Personnel; Resource Sharing; Running; Sampling; Sampling Studies; Science; Scientist; Site; Skin; Source; Specimen; Standardization; Strategic Planning; Synovial Membrane; Systemic Lupus Erythematosus; Systems Biology; Technology; Testing; Tissues; Translational Research; Traumeel S; United States; United States National Institutes of Health; Validation; Work; clinical database; clinical research site; cohort; comparative; in vitro Assay; invention; novel; patient population; peripheral blood; phase 1 study; phase 2 study; population based; programs; public health relevance; single-cell RNA sequencing; skin disorder; small molecule inhibitor; statistics; success; targeted treatment; treatment responders; validation studies

 DESCRIPTION (provided by applicant): The RFA states: "The overall goal of the AMP RA and Lupus Network (Network) is to define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of RA, lupus and related autoimmune diseases. Towards achieving this goal, a unique and novel infrastructure will be established, that uses a collaborative trans-disciplinary, integrated team science approach, to test high impact ideas that will: lay the foundation for a new and comprehensive understanding of mechanisms driving disease; stimulate early and applied research on cutting-edge technologies; and, advance the research enterprise by accelerating the discovery of disease pathways involved in autoimmune diseases." Our AMP RA and Lupus Network Leadership Center (LC) will enable all of these deliverables to be met. The goal of our LC is to establish a creative, nimble, and highly interactive group composed of leading scientists from throughout the United States (24 institutions across 14 States) and internationally - each with overlapping expertise in basic, clinical and translational research; technology invention, development, and implementation; unique bioinformatics and statistical methodology; and extensive interactions with biotechnology companies, pharmaceutical industry, disease foundations, NIH, and academic institutions. We have created a distributive model of leadership that takes advantage of the strengths of each of the participating investigators and centers, a model that we believe is necessary to complete the missions set forth in the AMP RFA. We will build a highly-functional infrastructure to meet not just the goals stated in the RFA, but to enable discoveries to be made that are truly transformative in RA and SLE, and are applicable to dozens of other autoimmune and inflammatory diseases. Very importantly, our proposal is not to create a model and infrastructure that will end in 2019, but rather to leverage this model to build a sustainable program that will accelerate discoveries in other disease areas, through funding from NIH, corporate partners, foundations, and philanthropy. The LC includes an LC Research Coordination, Management and Statistics Program (LCMP), a Systems Biology Research Group (SBG), and a Tissue Acquisition Research group (TRG), all of which are integrated and led by qualified faculty.

 描述（由适用提供）：RFA指出：“ AMP RA和狼疮网络（网络）的总体目标是定义共享和特定疾病的生物学途径，以确定与RA，狼疮和相关的自身免疫性疾病的治疗相关的药物目标，以实现这一目标，建立了一个独特的基础训练，该目标是建立的，该目标是建立的，验证型训练训练，该方法是验证的，该方法的训练始终是训练的训练，该方法是建立的，该方法是建立的，该验证者的态度始终是训练的训练训练，以实现训练培养基。将为促进疾病的机制的新的和全面的理解奠定了基础；我们的AMP RA和狼疮网络领导力中心（LC）将使所有这些可交付成果得到满足。我们的LC的目的是建立一个由来自美国的领先科学家（14个州的24个机构）组成的创意，灵活且高度互动的群体，在国际上 - 每个人都有重叠的专业知识 基础，临床和翻译研究；技术发明，开发和实施；独特的生物信息学和统计方法论；以及与生物技术公司，制药行业，疾病基金会，NIH和学术机构的广泛互动。我们创建了一个领导力的分配模型，该模型利用了每个参与调查员和中心的优势，我们认为这是一个模型 完成AMP RFA中规定的任务所必需的。我们将建立一个高度功能的基础架构，不仅满足RFA中所述的目标，还可以使发现在RA和SLE中真正具有变革性，并且适用于其他数十种自身免疫和感染疾病。非常重要的是，我们的建议不是建立将在2019年结束的模型和基础设施，而是要利用该模型来建立可持续的计划，该计划将通过NIH，公司合作伙伴，基金会和慈善事业的资金来加速其他疾病领域的发现。 LC包括LC研究协调，管理和统计计划（LCMP），系统生物学研究小组（SBG）和组织采集研究小组（TRG），所有这些研究小组（TRG）均由合格的教师整合和领导。